Having in hand CBA2 for stopping downstream effects of inheritance of APOEε4, together with unpublished results regarding a newly constructed foil for IL-1β that preliminarily suggests benefit in decreasing plaque and tangle formation, we are now in position to offer these two foils against the Two World promoters of Alzheimer’s and Parkinson’s and, as we believe, other neurodegenerative diseases characterized by aggregate accumulation. This evidence concerns the gene IL1B and Parkinson disease.